CDC advisers have recommended that for children ages 2 to 10 at risk for invasive meningococcal disease, the quadrivalent conjugate vaccine Menactra is preferable to the polysaccharide vaccine Menomune.
References and Resources
Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2–10 Years at Increased Risk for Invasive Meningococcal Disease.
Click Here to view notice.
Sponsored by The Doctor’s Channel